<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> is a class III antiarrhythmic agent that is frequently prescribed today for the treatment of ventricular and atrial <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> has many adverse effects, and one of them is thyroid dysfunction </plain></SENT>
<SENT sid="2" pm="."><plain>Advanced practice and staff nurses need to be vigilant, recognizing early signs and symptoms of thyroid dysfunction to prevent adverse drug reactions </plain></SENT>
<SENT sid="3" pm="."><plain>Often, the signs and symptoms of <z:chebi fb="0" ids="2663">amiodarone</z:chebi>-induced <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> are overlooked because of the complexity of the patient's condition </plain></SENT>
<SENT sid="4" pm="."><plain>The purpose of this article was to review a case study, present differential diagnoses and testing, discuss risk factors associated with <z:chebi fb="0" ids="2663">amiodarone</z:chebi>-induced <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo>, discuss its pathogenesis, and review clinical management </plain></SENT>
</text></document>